Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review

Affiliations

• ¹ Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
• ² Hypertension Unit, Instituto de Investigación imas12, Hospital Universitario, Madrid, Spain.
• ³ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
• ⁴ Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
• ⁵ University of Split School of Medicine, Split, Croatia.
• ⁶ Clinical Effectiveness Group, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.
• ⁷ Kantar Health GmbH, Real World Research & Value, Munich, Germany.
• ⁸ Vifor Pharma Group, Glattbrugg, Switzerland.
• ⁹ Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
• ¹⁰ Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden.